Eli Lilly/$LLY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Eli Lilly
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Ticker
$LLY
Sector
Primary listing
NYSE
Industry
Pharmaceuticals
Headquarters
Employees
47,000
ISIN
US5324571083
Website
Eli Lilly Metrics
BasicAdvanced
$725B
65.71
$12.29
0.47
$5.60
0.74%
Price and volume
Market cap
$725B
Beta
0.47
52-week high
$972.53
52-week low
$677.09
Average daily volume
4M
Dividend rate
$5.60
Financial strength
Current ratio
1.372
Quick ratio
0.569
Long term debt to equity
218.243
Total debt to equity
243.609
Dividend payout ratio (TTM)
43.74%
Interest coverage (TTM)
22.79%
Profitability
EBITDA (TTM)
22,003.3
Gross margin (TTM)
81.70%
Net profit margin (TTM)
22.66%
Operating margin (TTM)
41.41%
Effective tax rate (TTM)
18.34%
Revenue per employee (TTM)
$1,040,000
Management effectiveness
Return on assets (TTM)
16.54%
Return on equity (TTM)
77.28%
Valuation
Price to earnings (TTM)
65.711
Price to revenue (TTM)
14.821
Price to book
48.55
Price to tangible book (TTM)
192.19
Price to free cash flow (TTM)
-1,086.434
Free cash flow yield (TTM)
-0.09%
Free cash flow per share (TTM)
-74.33%
Dividend yield (TTM)
0.69%
Forward dividend yield
0.74%
Growth
Revenue change (TTM)
36.38%
Earnings per share change (TTM)
80.99%
3-year revenue growth (CAGR)
18.67%
10-year revenue growth (CAGR)
9.61%
3-year earnings per share growth (CAGR)
22.24%
10-year earnings per share growth (CAGR)
19.61%
3-year dividend per share growth (CAGR)
15.22%
10-year dividend per share growth (CAGR)
10.61%
What the Analysts think about Eli Lilly
Analyst ratings (Buy, Hold, Sell) for Eli Lilly stock.
Bulls say / Bears say
Eli Lilly's experimental oral drug, orforglipron, demonstrated significant weight loss and blood sugar reduction in a late-stage trial, positioning it as a strong competitor in the expanding obesity treatment market. (reuters.com)
Goldman Sachs projects that Eli Lilly's GLP-1 drugs, including Mounjaro and Zepbound, could drive a 140% surge in the company's shares by 2028, with revenues potentially reaching $400 billion. (markets.businessinsider.com)
Eli Lilly's experimental drug, lepodisiran, reduced lipoprotein(a) levels by 93.9% in a mid-stage trial, indicating potential in addressing genetic heart disease risk factors. (reuters.com)
CVS Health's decision to drop coverage of Eli Lilly's obesity drug Zepbound in favor of Novo Nordisk's Wegovy introduces pricing pressure and potential market share loss. (reuters.com)
The competitive landscape in the obesity drug market is intensifying, with companies like Roche entering the space, potentially challenging Eli Lilly's market dominance. (reuters.com)
Eli Lilly's stock experienced a decline of over 5% following CVS Health's reimbursement decision, reflecting investor concerns over pricing pressures and market competition. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 21 May 2025.
Eli Lilly Financial Performance
Revenues and expenses
Eli Lilly Earnings Performance
Company profitability
Eli Lilly News
AllArticlesVideos
5 Blue-Chip Giants That Have Paid Dividends for 100 Years and Longer
24/7 Wall Street·15 hours ago
Lilly to buy gene-editing partner Verve for $1.3 billion
CNBC Television·18 hours ago
Eli Lilly is making it cheaper and easier to buy high doses of blockbuster weight-loss drug Zepbound
Fast Company·20 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Eli Lilly stock?
Eli Lilly (LLY) has a market cap of $725B as of June 18, 2025.
What is the P/E ratio for Eli Lilly stock?
The price to earnings (P/E) ratio for Eli Lilly (LLY) stock is 65.71 as of June 18, 2025.
Does Eli Lilly stock pay dividends?
Yes, the Eli Lilly (LLY) stock pays dividends to shareholders. As of June 18, 2025, the dividend rate is $5.6 and the yield is 0.74%. Eli Lilly has a payout ratio of 43.74% on a trailing twelve-month basis.
When is the next Eli Lilly dividend payment date?
The next Eli Lilly (LLY) dividend payment date is unconfirmed.
What is the beta indicator for Eli Lilly?
Eli Lilly (LLY) has a beta rating of 0.47. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.